Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications-Reference-Cited by-同舟云学术

Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications

Published:2024-08-02 Issue: Volume: Page:
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Campbell Julie A.^ORCID,Henson Glen J.^ORCID,Ngwa Valery Fuh^ORCID,Ahmad Hasnat^ORCID,Taylor Bruce V.^ORCID,van der Mei Ingrid^ORCID,Palmer Andrew J.^ORCID,

Funder

MS Australia

Australian Government MRFF

University of Tasmania

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40273-024-01417-4.pdf

Reference46 articles.

1. Campbell JA, Jelinek GA, Weiland TJ, et al. SF-6D health state utilities for lifestyle, sociodemographic and clinical characteristics of a large international cohort of people with multiple sclerosis. Qual Life Res. 2020;29(9):2509–27.

2. Kuspinar A, Mayo NE. A review of the psychometric properties of generic utility measures in multiple sclerosis. Pharmacoeconomics. 2014;32:759–73.

3. Ahmad H, Campbell JA, Taylor BV, van der Mei I, Palmer AJ. The health economic impact of multiple sclerosis in Australia in 2017. Commissioned Report for MS Australia. https://www.msaustralia.org.au/wp-content/uploads/2018/08/health-economic-impact-of-ms-in-australia-in-2017_ms-research-australia_web.pdf.

4. The Multiple Sclerosis International Federation, Atlas of MS, 3rd Edition (September 2020). https://www.msif.org/resource/atlas-of-ms-2020.

5. Campbell JA, Simpson S Jr, Ahmad H, Taylor BV, van der Mei I, Palmer AJ. Change in multiple sclerosis prevalence over time in Australia 2010–2017 utilising disease-modifying therapy prescription data. Mult Scler. 2020;26(11):1315–28.